PHBI (Pharmagreen Biotech) ROE % Adjusted to Book Value: 0.00% (As of Jun. 2023)


What is Pharmagreen Biotech ROE % Adjusted to Book Value?

Pharmagreen Biotech PHBI ROE % Adjusted to Book Value is 0.00% as of Jun. 2023.

Pharmagreen Biotech's ROE % for the quarter that ended in Jun. 2023 was 0.00%. Pharmagreen Biotech's PB Ratio for the quarter that ended in Jun. 2023 was N/A. Pharmagreen Biotech's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was N/A.

Pharmagreen Biotech ROE % Adjusted to Book Value Related Terms

Pharmagreen Biotech ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Pharmagreen Biotech's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagreen Biotech ROE % Adjusted to Book Value Chart

Pharmagreen Biotech Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pharmagreen Biotech Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity 0.00 0.00 0.00 0.00

PHBI vs DVLP, CSTF, BLMS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's ROE % Adjusted to Book Value falls into.


Pharmagreen Biotech ROE % Adjusted to Book Value Calculation

Pharmagreen Biotech's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Pharmagreen Biotech's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Pharmagreen Biotech (PHBI) has a ROE % Adjusted to Book Value of 0.00% as of Jun. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pharmagreen Biotech and its competitors.
Is Pharmagreen Biotech's ROE % Adjusted to Book Value too high?
Pharmagreen Biotech's current ROE % Adjusted to Book Value is 0.00%.
How does Pharmagreen Biotech's ROE % Adjusted to Book Value compare to DVLP and CSTF?
Pharmagreen Biotech's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pharmagreen Biotech and its competitors. Pharmagreen Biotech's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current ROE % Adjusted to Book Value is 0.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagreen Biotech Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.